CD4 and neoplasm: Seventy-one percent of patients induced both CD4+ and CD8+ mKRAS-specific T cells and the induction of both CD4+ and CD8+ T cells significantly correlated with overall tumor biomarker response, indicating the potential importance of a balanced T cell response for improved tumor biomarker response (Fig. 2e,f).